NFKBIA (Ab-32/36) Antibody

What exactly does the NFKBIA (Ab-32/36) Antibody recognize?

The NFKBIA (Ab-32/36) Antibody specifically recognizes IκBα (inhibitor of NF-kappa B alpha) when it is phosphorylated at serine residues 32 and 36. This phosphorylation represents a critical regulatory step in the canonical NF-κB signaling pathway. The antibody enables detection of phospho-IκBα which signals the protein for ubiquitination and subsequent proteasomal degradation, a process that liberates NF-κB dimers to translocate to the nucleus .

Recent studies have demonstrated that in pluripotent stem cells, phosphorylated IκBα (p-IκBα) predominantly accumulates in the nucleus and is protected from degradation through K21 SUMOylation, which is detectable with this antibody by immunofluorescence analysis .

How does IκBα phosphorylation regulate the NF-κB signaling pathway?

IκBα phosphorylation at Ser32/36 represents a pivotal regulatory mechanism in NF-κB signaling. In the canonical pathway:

• External stimuli (e.g., cytokines, pathogens) activate the IκB kinase (IKK) complex

• IKK complex phosphorylates IκBα at serine residues 32 and 36

• Phosphorylated IκBα undergoes K48-linked polyubiquitination

• Ubiquitinated IκBα is degraded by the 26S proteasome

• NF-κB dimers (e.g., p65/p50) are released from cytoplasmic retention

• Liberated NF-κB translocates to the nucleus to activate target gene transcription

Research using proximity ligation assays (PLA) with NFKBIA (Ab-32/36) Antibody has shown that at the peak of pathway activation, p65/IκBα dimers decline in the cytoplasm while nuclear p65 increases, initiating the transcription of target genes including NFKBIA itself, creating a negative feedback loop .

What are optimal protocols for Western blot analysis using NFKBIA (Ab-32/36) Antibody?

For optimal Western blot results with NFKBIA (Ab-32/36) Antibody:

Sample Preparation:

• Lyse cells in buffer containing: 8M urea, 150 mM NaCl, 5 mM DTT, 50 mM Tris pH 8

• Supplement with protease inhibitors (Complete Protease Inhibitor Cocktail tablet)

• Add phosphatase inhibitors (Halt™ Protease and Phosphatase Inhibitor Cocktail)

• Centrifuge at 13,200 rpm for 15 min at room temperature

• Perform a second centrifugation step for clarification

Western Blot Protocol:

• Load 20-40 μg protein per lane

• Separate proteins on 10-12% SDS-PAGE

• Transfer to nitrocellulose membrane

• Block with 5% BSA in TBST for 1 hour

• Incubate with NFKBIA (Ab-32/36) Antibody (1:1000 dilution) overnight at 4°C

• Wash 3× with TBST

• Incubate with HRP-conjugated secondary antibody (1:5000)

• Develop using enhanced chemiluminescence

Expected Results: Phosphorylated IκBα appears as a band at approximately 40 kDa, with human 293 cells and mouse 3T3 cells showing strong reactivity .

How should I optimize immunofluorescence staining with this antibody?

Optimized Immunofluorescence Protocol:

• Fixation Options:

  • For fresh frozen tissue: Fix post-sectioning with 4% paraformaldehyde for 10 minutes

  • For cultured cells: Fix with 4% paraformaldehyde for 15 minutes at room temperature

  • Note: Prolonged fixation (overnight in 4% PFA) may significantly reduce epitope detection

• Permeabilization:

  • Use 0.1-0.2% Triton X-100 in PBS for 10 minutes at room temperature

• Blocking:

  • Block with 5% normal serum (from secondary antibody host species) + 0.3% Triton X-100 in PBS for 1 hour

• Antibody Dilution:

  • Prepare NFKBIA (Ab-32/36) Antibody at 1:100-1:200 dilution in antibody diluent

  • Incubate overnight at 4°C

• Controls:

  • Include cells treated with TNF-α or IL-1α (10 ng/ml, 30 min) as a positive control for IκBα phosphorylation

  • Include a negative control with non-specific IgG at matching concentration

Important Consideration: Research has demonstrated stark differences in epitope detection between fresh frozen and fixed tissues. For optimal results with NFKBIA (Ab-32/36) Antibody, validation by flow cytometry of antibody stains on nuclei isolated from frozen tissues is recommended prior to IF work .

What validation steps are necessary for confirming NFKBIA (Ab-32/36) Antibody specificity?

A thorough validation approach includes:

• Western Blot Validation:

  • Compare bands from control versus stimulated samples (e.g., TNF-α, IL-1α treated)

  • Verify molecular weight (approximately 40 kDa)

  • Include positive controls (e.g., 293 cells, 3T3 cells)

• Phosphatase Treatment Control:

  • Treat one sample set with lambda phosphatase prior to immunoblotting

  • Signal should disappear in phosphatase-treated samples

• Knockout/Knockdown Validation:

  • Use NFKBIA knockout cells or siRNA knockdown

  • Example: shRNA against p65 in cells as demonstrated in single-cell analysis studies

• Immunoprecipitation Validation:

  • Perform IP with anti-IκBα antibody followed by Western blot with NFKBIA (Ab-32/36)

  • For phospho-specific validation, IP protocol should include: lysis in buffer with 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM PMSF, 1 mM DTT, protease inhibitor cocktail, and 1 μM microcystin

• Peptide Competition:

  • Pre-incubate antibody with immunizing phosphopeptide

  • Signal should be blocked in the presence of the phosphopeptide

How can NFKBIA (Ab-32/36) Antibody be used for single-cell analysis of NF-κB signaling dynamics?

Recent advances in single-cell analysis of NF-κB dynamics using NFKBIA (Ab-32/36) Antibody include:

Proximity Ligation Assay (PLA) Approach:

• Fix cells at different time points after stimulation (e.g., IL-1α treatment)

• Apply PLA protocol to detect protein-protein interactions:

  • Use NFKBIA (Ab-32/36) Antibody in combination with anti-p65 antibody

  • This reveals the dynamic association/dissociation of phospho-IκBα and p65

• Combine with RNA FISH for NFKBIA mRNA detection to correlate with transcriptional readout

• Use this system to track the complete signaling cycle:

  • IκBα phosphorylation

  • Disruption of p65/IκBα interaction

  • Nuclear translocation of p65

  • Induced transcription of NF-κB target genes (including NFKBIA itself)

This methodology revealed that at 30 minutes post-IL-1α stimulation, p65/IκBα signals declined coinciding with nuclear translocation of p65 and activation of NF-κB target genes including NFKBIA itself .

What approaches can integrate NFKBIA (Ab-32/36) Antibody data with transcriptomic analysis?

Modern integrative approaches include:

Proteogenomic Analysis Framework:

• Parallel Sample Collection:

  • Process cells for NFKBIA (Ab-32/36) Antibody analysis via Western blot or RPPA (Reverse Phase Protein Array)

  • Simultaneously extract RNA for transcriptomic analysis

• Dynamic Temporal Analysis:

  • Apply stimuli (e.g., cytokines, anticancer drugs) at multiple concentrations

  • Collect samples at multiple time points (e.g., 5 time points over 24 hours)

  • Track IκBα phosphorylation using NFKBIA (Ab-32/36) Antibody via RPPA

  • Correlate with transcriptomic changes

• Single-Cell Multi-Omics Approach:

  • Apply inCITE-seq (intranuclear proteins and RNA) methodology

  • Combine NFKBIA (Ab-32/36) Antibody staining with RNA-seq in single cells

  • This approach reveals heterogeneity in NF-κB pathway activation across cell populations

Analysis Pipeline:

• Use bioinformatic tools to correlate phospho-IκBα levels with gene expression patterns

• Generate network models of NF-κB-regulated transcriptional programs

• Identify key nodes and feedback mechanisms in the regulatory network

How does NFKBIA (Ab-32/36) Antibody contribute to understanding cancer resistance mechanisms?

NFKBIA (Ab-32/36) Antibody has been instrumental in elucidating cancer therapy resistance mechanisms:

Breast Cancer Applications:

• Studies show that glucocorticoid receptor antagonists combined with anticancer agents can overcome resistance

• NFKBIA (Ab-32/36) Antibody helps track changes in NF-κB activity after treatment

• Research revealed activation of survival pathways mediated by altered IκBα phosphorylation

Leukemia Research:

• Screening of compounds targeting NF-κB identified emetine as a potential anti-leukemia agent

• NFKBIA (Ab-32/36) Antibody tracking showed effects against human AML cells transplanted into NSG mice

• Similar effects were observed with proteasome inhibitor Bortezomib, affecting NF-κB activity and inducing oxidative stress primarily in leukemic stem cells

Mechanistic Insights:

• Divergent processing of cell stress signals forms the basis of cancer resistance

• Through phospho-IκBα detection, researchers identified differential responses to therapy between cancer cells and normal tissue

• This has led to development of combination therapies targeting both NF-κB components and stress response elements

Why might I observe variable or weak staining with NFKBIA (Ab-32/36) Antibody in tissue samples?

Variable staining may result from several factors:

Recent validation studies demonstrated that different antibodies targeting the same epitope exhibited stark contrast in detection depending on tissue processing. One version of an antibody was unable to detect epitopes in frozen tissue, while another version exhibited clean epitope detection in frozen but not in overnight fixed tissue .

What controls are essential for cell-based ELISA using NFKBIA (Ab-32/36) Antibody?

For reliable cell-based ELISA results, implement these controls:

Positive Controls:

• Include wells treated with known NF-κB pathway activators:

  • TNF-α (10 ng/ml, 5-30 min)

  • IL-1α (10 ng/ml, 5-30 min)

  • PMA (100 ng/ml, 30-60 min)

Negative Controls:

• Include wells with:

  • Pathway inhibitors (e.g., IKK inhibitor)

  • Untreated/unstimulated cells

  • Non-specific IgG antibody at same concentration as primary antibody

Normalization Controls:

• Include GAPDH antibody staining in parallel wells

• This enables normalization of phospho-IκBα signal to total protein content

• Critical for comparing signals across different treatment conditions

Technical Controls:

• Include wells without primary antibody

• Include wells without secondary antibody

• Test antibody across a range of dilutions for optimization

According to established protocols, measuring the ratio of phospho-IκBα signal normalized to GAPDH provides the most reliable quantitative results for comparing relative phosphorylation levels across experimental conditions .

How can I address contradictory data when using NFKBIA (Ab-32/36) Antibody across different experimental systems?

When facing contradictory results:

• Consider Cellular Localization Differences:

  • Recent research has shown that phosphorylated IκBα localizes differently in various cell types

  • In pluripotent stem cells, p-IκBα accumulates in the nucleus and chromatin fractions

  • In cancer cells, localization patterns may vary with disease state and treatment

• Assess Technical Variables:

  • Antibody concentration significantly impacts detection

  • Multiple studies demonstrate that signals vary across a wide range of antibody concentrations

  • Optimization is essential for each experimental system

• Evaluate Sample Processing Effects:

  • For cell fractionation studies, verify clean separation of cytoplasmic and nuclear fractions

  • Use additional markers (e.g., GAPDH for cytoplasm, Lamin B for nucleus)

  • Protect phosphorylation status with phosphatase inhibitors throughout processing

• Consider Dynamic Temporal Effects:

  • NF-κB signaling is highly dynamic

  • Sample collection timing relative to stimulation is critical

  • Different cell types may exhibit different activation kinetics

  • When comparing results, ensure time points match precisely

• Reconciliation Approach:

  • When contradictions arise, implement a multi-method approach:

    • Combine Western blot, IF, and flow cytometry

    • Use multiple antibodies targeting different epitopes of IκBα

    • Validate key findings with genetic approaches (siRNA, CRISPR)

How can NFKBIA (Ab-32/36) Antibody contribute to single-cell transcriptomic studies?

Recent advances in inCITE-seq (intracellular protein and RNA detection) methodology demonstrate powerful applications:

Technical Implementation:

• Optimize NFKBIA (Ab-32/36) Antibody concentration through titration experiments

• Validate antibody specificity via flow cytometry on isolated nuclei

• Apply the optimized antibody in conjunction with RNA-seq workflows

• This enables correlation between phospho-IκBα levels and transcriptional profiles at single-cell resolution

Research Applications:

• Identifying subpopulations with differential NF-κB activity in heterogeneous samples

• Correlating phospho-IκBα levels with specific transcriptional programs

• Tracking response to therapy at the single-cell level in complex tissues

Studies have validated this approach in mouse brain tissue, demonstrating that antibody signals varied across a wide range of concentrations, underscoring the importance of choosing an appropriate concentration regime for experimental design .

What are the considerations for using NFKBIA (Ab-32/36) Antibody in tumor-educated platelets (TEP) research?

Tumor-educated platelets represent an emerging area where NFKBIA (Ab-32/36) Antibody can provide valuable insights:

Experimental Design Considerations:

• Platelets can respond to external signals by altering RNA profiles

• Cancer-associated platelets may show differential NF-κB pathway activation

• NFKBIA (Ab-32/36) Antibody can track phospho-IκBα as a marker of altered platelet function

Research Applications:

• Studying how tumor-derived signals affect platelet NF-κB pathway activation

• Investigating the contribution of platelet NF-κB signaling to cancer progression

• Exploring platelets as potential biomarkers through combined protein and RNA analysis

Recent research has shown that platelets demonstrate RNA splicing in response to tumor-associated signals, with NFKBIA being one of the transcripts potentially affected. Using NFKBIA (Ab-32/36) Antibody in combination with transcriptomic analysis could reveal how phosphorylation status correlates with RNA processing events in platelets during cancer progression .

Bibliography

• US Patent 12062444 B2 - Methods of treating breast cancer with a glucocorticoid receptor antagonist

• Epigenetic modifications driving ground state pluripotency exit

• Joint single-cell measurements of nuclear proteins and RNA in vivo

• Applications of Transcriptomics in the Research of Antibody-Mediated Rejection

• NFKBIA (Ab-32/36) Antibody antibody CSB-PA593749

• Cancer diagnostics using mRNA sequencing of tumor-educated platelets

• NFKBIA / IKB Alpha / IKBA Cell-Based ELISA Kit User Manual

• Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases

• Single-Cell Analysis of Multiple Steps of Dynamic NF-κB Regulation in Control and IL-1α-Stimulated Cells

• Single-Cell Analysis of Multiple Steps of Dynamic NF-κB Regulation in Control and IL-1α-Stimulated Cells

• Applications of Transcriptomics in the Research of Antibody-Mediated Rejection

• An Integrated Genomic, Proteomic, and Immunopeptidomic Analysis to Measure How IFN-γ Shapes the Presented Immunopeptidome

• Human papillomavirus-related neoplasia of the ocular adnexa

• Consideration of underlying immunodeficiency in refractory or recalcitrant warts

• Dynamic phospho-proteogenomic analysis of gastric cancer cells

• Divergent Processing of Cell Stress Signals as the Basis of Cancer Treatment Response

Recent Publications Using NFKBIA (Ab-32/36) Antibody